Overview

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, single-arm, prospective, phase II study. conducted to evaluate the efficacy, safety and tolerability of nab-paclitaxel plus pyrotinib in patients with lymph node-negative and tumor size ≤3 cm, HER2 positive breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel